Clinical outcomes of CO₂-less single-port video-assisted thoracoscopic thymectomy versus open thymectomy: comparative study

Javier Aragón, Itzell Pérez Méndez, Alexia Gutiérrez Pérez

Department of Thoracic Surgery, Asturias University Central Hospital, Asturias, Spain

Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: J Aragón, IP Méndez; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Javier Aragón, MD. Chief of Minimally Thoracic Invasive Unit, Department of Thoracic Surgery, Asturias University Central Hospital, C/Luis Fernández Castañón 2, 2 B; 33013 Oviedo, Asturias, Spain. Email: jaragonvalverde@gmail.com.

Background: Although video-assisted thoracoscopic surgery (VATS) for thymic disorders has been introduced, its oncological outcome and benefits over others open approaches remains unclear. Single-port VATS thymectomy using a flexible port and CO₂ has been described. However, VATS thymectomy is possible by a single incision of 3 cm without CO₂ insufflation or special port device avoiding objections related to CO₂ insufflation and allowing instruments to move more freely making procedure easier and cheaper. Our institutional experience in open and CO₂-less VATS single-port thymectomy was retrospectively reviewed to evaluate compared to sternotomy, the clinical and oncological outcomes with this novel approach.

Methods: A retrospective review consisting of 84 patients who underwent thymectomy because different thymic disorders especially thymoma was performed. Eighteen patients underwent CO₂-less VATS single port thymectomy, while 66 underwent thymectomy through open sternotomy. Many clinical factors associated with the surgical and clinical outcomes, including tumor recurrence and clinical remission, were recorded.

Results: Non major postoperative complications were observed in any group. The median operative time and postoperative hospital stay of CO₂-less VATS single port thymectomy were 95 min and 1 day, respectively and 120 min and 7 days for open sternotomy. The thymoma was the most common thymic disorder with 7 patients (38%) in VATS group and 28 patients (42.4%) for the open approach. The median lesion size was 2.6 cm in the VATS group and 3.2 cm in the open approach. No thymoma recurrence in patients undergoing VATS was observed during the follow-up time, while in the open surgery group 14.28% recurrence was observed, distributed as follows: loco-regional 75% and 25% at distance; free disease period of these patients was 8.3 months. Thymectomy associated with myasthenia gravis (MG) was observed in 6 (33%) patients in the VATS group and 32 (48%) patients for sternotomy; our results regarding thymectomy for the treatment of MG were established by the MG post-intervention status [complete stable remission (CSR), pharmacologic remission, minimal manifestations, improved, unchanged and worse exacerbation, and died of MG] and reflected similar results in both approaches.

Conclusions: CO₂-less VATS single-port thymectomy is a feasible and safe procedure. Oncologic outcomes are similar to open approaches. Complications, surgical time and hospital stay are shorter compared with sternotomy. This is an initial experience, further work is required to evaluate long-term results.

Keywords: Thymectomy; video-assisted thoracoscopic surgery single port (VATS single port); thymic disorders; sternotomy; myasthenia

Received: 26 February 2016; Accepted: 28 February 2016; Published: 30 March 2016.

doi: 10.21037/jovs.2016.03.07

View this article at: <http://dx.doi.org/10.21037/jovs.2016.03.07>

Introduction

Thymectomy traditionally have been performed by sternotomy, but because of the invasiveness of the traditional approach leading to long time of recovery, minimal invasive approaches have gained progressively interest to the point of being recognized as the surgery of choice for the management of mediastinal tumors, including thymoma (1-3).

The first minimal invasive thymectomy, was introduced in 1992, and over the next two decades, many different approaches have been described: video-assisted thoracoscopic surgery (VATS) multiport thymectomy, transcervical thymectomy, subxiphoid approach for extended thymectomy, robotic thymectomy and uniportal VATS thymectomy. However, the oncological feasibility and limitations of the minimally invasive thymectomy remain controversial (1-6).

VATS thymectomy is a procedure which usually requires carbon dioxide (CO₂) gas in order to gain enough visualization. Single-port VATS has been described by using a flexible port (SILS port®, Covidien, MA©) designed to retain gas. We have hypothesized that VATS thymectomy is feasible by a single incision without using CO₂, with similar outcome to conventional VATS.

This article presents our initial experience with “CO₂-less VATS single port thymectomy” during a period of 3 years. In this novel approach, complete thymectomy is performed by a 3-cm thoracic single incision, without use CO₂ gas, port device or chest retractor. The factors associated with the surgical and clinical outcomes were retrospectively reviewed to evaluate feasibility and limitations of CO₂-less VATS single port thymectomy in comparison with open approach.

Materials and methods

We retrospectively reviewed files of 84 patients undergoing thymectomy for treatment of different thymic disorders specially thymoma with a curative intent between January 2005 and January 2016 in the minimally thoracic invasive unit of Asturias University Central Hospital. The institutional ethical review board of the Asturias University Central Hospital provided the approval for this study, and all patients provided written informed consent before operation.

Surgical time, postoperative hospital stay, intraoperative outcomes and postoperative complications were recorded. Patients diagnosed of thymoma were followed by chest CT at 6 and 12 months after surgery and once yearly thereafter. The diagnoses of all resected thymomas, surgical margins and Masaoka stages (7) were confirmed by histopathological

examination. Tumors were classified histologically according to the World Health Organization (WHO) classification into types A, AB, B1, B2, B3 and thymic carcinoma (8). In case of thymectomy for myasthenia gravis (MG) patients were followed by clinical interview every 6 months. Criteria for the assessment of the postoperative status during the follow-up were referred to definitions given in the MG post-intervention status, including: complete stable remission (CSR), pharmacologic remission, minimal manifestations, improved, unchanged and worse exacerbation, and died of MG (9).

Statistical analysis

All the data are reported as median or frequencies, with associated interquartile ranges (IQR), 95% confidence intervals (CI), and P values calculated. Categorical data, both nominal and ordinal, were compared between groups using Fisher's χ^2 (exact) test. A probability value of less than 0.05 was considered to be statistically significant. SPSS, version 20.0 (IBM Corp.) was used for the statistical analysis.

Operative procedure

A complete extended thymectomy (including superior and inferior poles) and surrounding fat tissues were resected in both open and VATS procedures.

CO₂-less single port procedure

A double-lumen tube for selective-lung ventilation with continuous aspiration was used in order to gain full collapse of the no dependent lung. Lesser tidal volume for optimal ventilation was applied to dependent lung. Patients were placed in lateral decubitus position. A 3-cm incision was placed on the left hemithorax in the fourth intercostal space between the anterior and middle axillary line (*Figure 1*). For a panoramic view, a 5-mm/30° thoracoscope was used; which was introduced through the anterior part of the incision. However, the placement of thoracoscope was modified at times according to the requirements of some particular step during procedure. For avoid crowding of instruments, specific uniportal VATS instruments (Scanlan Uniportal/Single-Incision®, Scanlan International US©) were used. Phrenic nerve is identified. Mediastinal pleura are incised just anterior to the phrenic nerve in its upper part. This incision is followed all along the nerve pathway to the

Figure 1 Patient placement and incision.

point it is not in contact with mediastinal fat. Dissection of cranial part is carried out to identify left brachiocephalic vein which is dissected using an ultrasonically activated device (Harmonic®, Ethicon US©) for vascular branches. Once brachiocephalic vein is dissected, a blunt separation is used for separated the thymus gland to the sternum as far contralateral pleura is visualized. The thymus was then carefully dissected cranially over the left brachiocephalic vein by traction of thymus pole. All thymic lobes and perithymic fatty tissues were mobilized en bloc with the tumor, allowing exposure of the underlying pericardium and the aorta. After the left side of the thymus was dissected from the superior pole to the inferior pole, the dissection was continued to the right thymic lobe. Thymus is mobilized free from the pericardium and ascending aorta. The specimen was removed in a plastic retrieval bag. An 8-French drain catheter is left in place through the surgical incision.

Results

Patient and tumor characteristics

We performed 84 consecutive surgical procedures for different thymic disorders, most common was thymoma with 35 patients (41.7%) followed by thymic cyst with 24 patients (28.5%), thymic hyperplasia with 13 patients (15.5%), thymic remnant with 11 patients (13.1%) and one ectopic parathyroid gland (1.2%). Of them, 18 (21.42%) patients underwent CO₂-less VATS single-port thymectomy, while 66 (78.58%) underwent thymectomy through an open sternotomy. Patient characteristics were not significantly different between approaches (*Table 1*).

Table 1 Patients and tumor characteristics

Characteristics	VATS single port	Open surgery
Patients & tumor characteristics		
Sex, N° (%)		
Male	6 (33.3)	27 (40.9)
Female	12 (66.7)	39 (59.1)
Age, mean ± SD [range]	56±12 [33–81]	55±17 [16–86]
Myasthenia associated, N° (%)		
Yes	6 (33.3)	32 (48.5)
No	12 (66.7)	34 (51.5)
Tumor size (cm)	2.8±2.3	3.6±3.2
Thymic disorder, N° (%)		
Thymoma	5 (33.3)	28 (43.1)
Thymic hyperplasia	1 (6.7)	12 (18.5)
Thymic remnant	3 (20.0)	8 (12.3)
Thymic cyst	6 (40.0)	17 (26.2)
Comorbidity, N° (%)		
Respiratory diseases	1 (6.7)	4 (7.8)
Cardiovascular diseases	1 (6.7)	2 (3.9)
Respiratory diseases + cardiovascular diseases	1 (6.7)	3 (5.9)
Cardiovascular diseases + other	1 (6.7)	3 (5.9)
Others	11 (73.3)	39 (76.5)
Masaoka stage, N° (%)		
I	3 (42.9)	15 (53.6)
IIA	3 (42.9)	6 (21.4)
IIB	1 (14.3)	2 (7.1)
III	0 (0)	2 (7.1)
IVA	0 (0)	3 (10.7)
WHO classification, N° (%)		
A	0 (0)	9 (32.1)
AB	3 (42.9)	8 (28.6)
B1	1 (14.3)	3 (10.7)
B2	3 (42.9)	5 (17.9)
B3	0 (0)	2 (7.1)
C	0 (0)	1 (3.6)

VATS, video-assisted thoracoscopic surgery; N°, patients sample; SD, standard deviation.

Table 2 Postoperative outcomes

Outcomes	VATS single port	Open surgery	P value
Surgery time, mean $\pm$ SD [range]	95 $\pm$ 36 [60–170]	120 $\pm$ 59 [60–300]	0.126
Postoperative hospital stay (days), mean $\pm$ SD [range]	1 $\pm$ 0.6 [1–3]	7 $\pm$ 7,512 [4–54]	<0.002
Postoperative hospital stay (days), mean $\pm$ SD [range]	1 $\pm$ 1 [1–2]	3.5 $\pm$ 2 [1–11]	<0.002
Follow-up recurrence, N° (%)			0.157
Yes	0 (0.00)	4 (14.29)	
No	7 (100.00)	24 (85.71)	

VATS, video-assisted thoracoscopic surgery; SD, standard deviation; N°, patients sample.

Intraoperative outcomes

Of the 18 cases performed by CO₂-less VATS single port thymectomy, there were no intraoperative complications that prevented completion of the resection by VATS. No conversions or incision lengthening were required in any case. Mean surgical time was 101.3 $\pm$ 36.6 min in VATS group and 118.11 $\pm$ 59.5 in open resection group (P=0.126). There was an important hemorrhage in one case in the open group. The mean of tumor size was 2.81 $\pm$ 2.3 cm in VATS groups and 3.62 $\pm$ 3.2 cm in open resection group (P=0.327).

Postoperative outcomes

The median hospital stay was one day (range, 1–3) in VATS group and 7 days (range, 4–54) in open resection group (P<0.002). The median chest tube duration was one day (range, 1–2) in VATS group and 7 days (range, 1–11) in open resection group (P<0.002). The intensive care unit median time was 24 hours in open cases and 10 hours in VATS procedures.

The most relevant data about intraoperative and postoperative findings are collected in *Table 2*.

Most common complication in the open approach group was wound infection (n=2, 3%). There was one death (1.19%) in this group because a very old female with 81 years old, who underwent an open thymectomy for treatment of uncontrolled MG suffering a significant blood loss during surgery. Patient died 10 days post-operatively because a neurological disorder. No complications or deaths in the group of patients undergoing VATS were found.

Of the 35 patients who underwent thymectomy for thymoma 18 patients were stage I (51.42%), 9 patients stage IIa (25.71%), 3 patients stage IIb (8.5%), 2 patients stage III (5.7%) and 3 patients stage IVa (8.5%). The mean follow-up

time was 16.5 $\pm$ 14.6 min in VATS groups and 61.6 $\pm$ 31 in open resection group. In the comparative analysis, for the follow-up period (12 months) we found that both the 5-year overall and 5-year recurrence-free survival rates were 100% for VATS group but 100% and 94%, respectively for open surgery. Histopathological analysis shows complete and extended thymectomy achieved in all patients. Unexpected R1 status was found in one patient in the open group. This patient was sent to the medical oncology service to complete treatment with adjuvant radiotherapy.

Regarding thymectomy associated with MG, we founded 6 cases (33%) in the VATS group and 32 (48%) patients for sternotomy. According with classification of MG severity (Osserman classification) patients were distributed as follows: 7 patients stage I (18.4%), 14 patients stage IIa (36.8%), 14 patients IIb (36.8%) and three patients stage III (7.8%). All patients in the VATS group were stage II. MG post-intervention status was distributed as: 5 patients (13.15%) had a complete and stable remission, 14 patients (36.84%) pharmacologic remission and 19 patients (50%) were unchanged. All patients with complete remission belonged to open group. The distribution of outcomes for different approaches is shown in *Table 3*.

Discussion

First thymectomy for treatment of MG is attributed to Sauerbruch, who performed a thymectomy by cervical approach in 1911. Likewise, Blalock performed first thymectomy by sternotomy in 1936 for treatment of thymoma. Minimal invasive thymectomy was introduced in 1992 (1,10,11).

In a relatively short period of time, minimally invasive approach has been gained interest for many diagnostic and therapeutic mediastinal procedures previously performed by traditional sternotomy. Nowadays minimally invasive

Table 3 Thymectomy associated with myasthenia gravis results

Characteristics	VATS single port, N° (%)	Open surgery, N° (%)
Osserman classification		
I	0 (0)	7 (21.9)
IIA	3 (50)	11 (34.4)
IIB	3 (50)	11 (34.4)
III	0 (0)	3 (9.4)
MG post-intervention status		
Complete stable remission	0 (0)	5 (15.6)
Pharmacologic remission	3 (50)	11 (34.4)
Unchanged	3 (50)	16 (50)

VATS, video-assisted thoracoscopic surgery; N°, patients sample; MG, myasthenia gravis.

surgery is considered the eligible approach for treatment of early-stage of thymoma and other indications for thymectomy (1,2). In this sense, different approaches have been proposed: multiport VATS thymectomy, transcervical thymectomy, subxiphoid approach, and uniportal VATS; all of them with similar results. VATS thymectomy for thymic disorders has showed comparative results with conventional open thymectomy (12). More recently, thoracoscopic thymectomy with Da Vinci robotic system has been developed (13) but its advantages remains controversial.

As far our knowledge, there are very few series reporting surgical outcomes of single-port thymectomy. In all cases reviewed, CO₂ was used requiring a special port (SILS port®, Covidien, MA©) to retain gas (14). However, single-port VATS thymectomy without the use of CO₂ and hence any special port device is possible but up till now has not been described.

Intrathoracic CO₂ insufflation helps the surgeons by increasing the surgical field during thoracoscopy, but numerous studies showed that positive pressure of capnothorax had negative impact on patients, forcing to a very strict gas flow control and extensive haemodynamic motorization, to avoid these adverse effects (15). Most common CO₂ insufflation adverse effect is hypercapnia with increased cardiac output, central venous oxygen (O₂), and arterial O₂ tension (16); hypercapnia may progress to hypercapnic acidosis, with increased of cerebral blood flow and local blood cell damage (17). Byhahn C, at all found adverse effects of hypercapnia induced by CO₂ insufflation are worse in patients with lower forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC), increased

age and smoking history (18). Based on these arguments we consider CO₂-less single port, described in our study, may be a beneficial progress in minimal invasive thymectomy.

In addition, given that single-port technique is performed introducing all instruments thru the same incision, instruments need to move as free as possible along the port. In this respect it is striking that CO₂-less VATS don't need any port device enabling more space to move instruments and camera more freely making the procedure easier and cheaper.

Several authors (19,20) have reported that complete thymus resection is always the treatment of choice for majority of thymic disorders. However, no definitive guidelines have been established regarding the optimal surgical procedure or resection extent for majority of thymic disorders. In addition, Sakamaki *et al.* (21) reported that unnecessary wide resection of the thymus for smaller lesions, may increase the potential risk of surgical complications in some cases.

In the basis of our 4-year experience in uniportal VATS for lung major resection, and our experience in CO₂-less 3 ports VATS thymectomy, we began to perform complete and extended thymectomy by a single incision without gas in the aim to deploy the most minimal invasive technique.

For patients with diagnostic of thymoma in this study, both the 5-year overall and 5-year recurrence-free survival rates were 100% during the follow-up period for VATS groups and 100% and 94%, respectively for open surgery showing any advantage for sternotomy. This results are concordant with others authors. A recent report of surgical treatment for thymoma demonstrated that the overall 5-year survival rate of patients with stages II thymomas and I ranged from 89% to 100% and 71% to 95%, respectively (22).

In our study, rates of complete remission for MG thymectomy were 13.5% in the first year of follow-up and exclusive for open surgery group; this is comparable to other large studies showing similar rates of complete remission after complete thymectomy (23). Mantegazza *et al.* in their large multicentre follow-up reported a CSR of 11% at the 5-year follow-up. They concluded that remission rate (RR), raised in: patients operated shortly after diagnosis, generalized mild-to-moderate MG, and involuted thymus (24). Venuta *et al.* in their 27-year experience review reported a 25% CSR at the 10-year follow-up (23).

The mid-term surgical outcomes in our series demonstrated a very significant shorter hospital stay (median one day), and intensive care stay (median 10 hours) for VATS group. In the same way, complications in this series

were exclusive for open surgery group evidencing the safety and feasibility of this novel approach.

Our study has several limitations. This study is a non-randomized retrospective study and in this sense with potential selection bias. In addition, as consequence of the novelty of this technique, the number of patients were different for two groups and are not sufficiently large to obtain definitive conclusions. Furthermore, because thymic disorders are usually indolent disease, longer follow-up is needed to determine the outcomes of CO₂-less single-port VATS. Until there are other similar experiences, our results should be interpreted with caution.

Conclusions

CO₂-less VATS single-port thymectomy is a feasible and safe procedure with good postoperative and mid-term oncologic outcomes. Complications, surgical time and hospital stay are shorter compared with sternotomy. Further work is required to evaluate the long-term results.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The institutional ethical review board of the Asturias University Central Hospital provided the approval for this study. Written informed consent was obtained from the patient for publication. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

References

1. Toker A, Sonett J, Zielinski M, et al. Standard terms, definitions, and policies for minimally invasive resection of thymoma. *J Thorac Oncol* 2011;6:S1739-42.
2. Rückert JC, Ismail M, Swierzy M, et al. Minimally invasive thymus surgery. *Chirurg* 2008;79:18, 20-5.
3. Mack MJ, Landreneau RJ, Yim AP, et al. Results of video-assisted thymectomy in patients with myasthenia gravis. *J Thorac Cardiovasc Surg* 1996;112:1352-9; discussion 1359-60.
4. Shiono H, Ohta M, Okumura M. Open video-assisted techniques: thoracoscopic extended thymectomy with bilateral approach and anterior chest wall lifting. In: Lavini C, Moran CA, Morandi U, et al., editors. *Thymus Gland Pathology: Clinical, Diagnostic and Therapeutic Features*. Milan: Springer, 2008:187-94.
5. Ohta M, Hirabayashi H, Okumura M, et al. Thoracoscopic thymectomy using anterior chest wall lifting method. *Ann Thorac Surg* 2003;76:1310-1.
6. Augustin F, Schmid T, Sieb M, et al. Video-assisted thoracoscopic surgery versus robotic-assisted thoracoscopic surgery thymectomy. *Ann Thorac Surg* 2008;85:S768-71.
7. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. *Cancer* 1981;48:2485-92.
8. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. *Cancer* 2002;94:624-32.
9. Common Data Element: Myasthenia Gravis Foundation of America (MGFA) - post-intervention status. Available online: <https://fitbir.nih.gov/portal/publicData/dataElementAction!view.action?dataElementName=MFGAPostIntervntnStatus&publicArea=true>
10. Viets HR, Schwab RS. *Thymectomy and Myasthenia Gravis*, Springfield, Illinois: Thomas, 1960.
11. Blalock A, Mason ME, Morgan HJ, et al. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. *Ann Surg* 1939;110:544-61.
12. Rückert JC, Ismail M, Swierzy M, et al. Thoracoscopic thymectomy with the da Vinci robotic system for myasthenia gravis. *Ann N Y Acad Sci* 2008;1132:329-35.
13. Pennathur A, Qureshi I, Schuchert MJ, et al. Comparison of surgical techniques for early-stage thymoma: feasibility of minimally invasive thymectomy and comparison with open resection. *J Thorac Cardiovasc Surg* 2011;141:694-701.
14. Scarci M, Pardolesi A, Solli P. Uniportal video-assisted thoracic surgery thymectomy. *Ann Cardiothorac Surg* 2015;4:567-70.
15. Raumanns J, Diegeler A, Falk V, et al. Hemodynamic effects of CO₂ insufflation under one-lung ventilation for roboter-guided thoracoscopic surgery. *Anesth Analg* 2000;90:SCA 55.
16. Mukhtar AM, Obayah GM, Elmasry A, et al. The therapeutic potential of intraoperative hypercapnia during video-assisted thoracoscopy in pediatric patients. *Anesth Analg* 2008;106:84-8, table of contents.
17. Landenhed M, Al-Rashidi F, Blomquist S, et al. Systemic effects of carbon dioxide insufflation technique for de-

- airing in left-sided cardiac surgery. *J Thorac Cardiovasc Surg* 2014;147:295-300.
18. Byhahn C, Mierdl S, Meininger D, et al. Hemodynamics and gas exchange during carbon dioxide insufflation for totally endoscopic coronary artery bypass grafting. *Ann Thorac Surg* 2001;71:1496-501; discussion 1501-2.
 19. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. *Ann Thorac Surg* 1995;60:908-13; discussion 914.
 20. Singhal S, Shrager JB, Rosenthal DI, et al. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. *Ann Thorac Surg* 2003;76:1635-41; discussion 1641-2.
 21. Sakamaki Y, Kido T, Yasukawa M. Alternative choices of total and partial thymectomy in video-assisted resection of noninvasive thymomas. *Surg Endosc* 2008;22:1272-7.
 22. Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. *Ann Thorac Surg* 2008;86:673-84.
 23. Venuta F, Rendina EA, De Giacomo T, et al. Thymectomy for myasthenia gravis: a 27-year experience. *Eur J Cardiothorac Surg* 1999;15:621-4; discussion 624-5.
 24. Mantegazza R, Beghi E, Pareyson D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. *J Neurol* 1990;237:339-44.

doi: 10.21037/jovs.2016.03.07

Cite this article as: Aragón J, Pérez Méndez I, Gutiérrez Pérez A. Clinical outcomes of CO₂-less single-port video-assisted thoracoscopic thymectomy versus open thymectomy: comparative study. *J Vis Surg* 2016;2:71.